Literature DB >> 2986897

The pathology of cervical cancer.

M C Anderson.   

Abstract

The preinvasive phase of squamous cell carcinoma of the cervix is a continuous spectrum of abnormal epithelium, which, for convenience of classification and as a guide to management, is customarily subdivided into three grades. The histological diagnosis of CIN, as well as the distinction between the grades, depends on a combination of features embracing aspects of differentiation, nuclear changes and mitotic activity. Grading of CIN is subjective. Generally, a minor degree of CIN would be expected to progress to a more severe form if not treated, but this progression does not seem to be inevitable; the more severe a CIN is at the time of diagnosis, the more likely it is that it will progress, both to a more severe degree of CIN and, eventually, to invasive carcinoma. Conversely, the more minor the degree of CIN at diagnosis, the more likely it is that it will regress. True figures are not available for the rate of progression from CIN to invasive carcinoma; it is sufficient to accept that the risk of progression probably occurs in a significant proportion of cases, if not the majority. Preclinical invasive carcinoma is divided into microinvasive carcinoma and occult invasive (Stage Ib) carcinoma. The definitions of these lesions have not yet been satisfactorily established; the term microinvasive carcinoma should define the maximum size of tumour which has virtually no metastatic potential and so may be treated in a conservative fashion. Invasive squamous cell carcinoma is classified histologically according to the cell type and the degree of differentiation, although it is debatable whether the cell type has any correlation with prognosis. Adenocarcinomas make up 5-10% of cervical cancers and a variety of histological types have been recognized. Adenocarcinoma in situ is being diagnosed with increasing frequency, often in association with squamous CIN. It seems apparent that AIS is a precursor of adenocarcinoma, but little is known about its natural history.

Entities:  

Mesh:

Year:  1985        PMID: 2986897

Source DB:  PubMed          Journal:  Clin Obstet Gynaecol        ISSN: 0306-3356


  7 in total

1.  Carcinoma of the cervix: an infectious disease.

Authors:  J V Mackel; E H Krikke
Journal:  Can Fam Physician       Date:  1989-06       Impact factor: 3.275

Review 2.  Sex and cervical cancer.

Authors:  J D Oriel
Journal:  Genitourin Med       Date:  1988-04

3.  Human papillomavirus and the three group metaphase figure as markers of an increased risk for the development of cervical carcinoma.

Authors:  E C Claas; W G Quint; W J Pieters; M P Burger; W J Oosterhuis; J Lindeman
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

4.  Investigation of expression of 5T4 antigen in cervical cancer.

Authors:  H Jones; G Roberts; N Hole; I W McDicken; P Stern
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

5.  Increased activity of 6-phosphogluconate dehydrogenase and glucose-6-phosphate dehydrogenase in purified cell suspensions and single cells from the uterine cervix in cervical intraepithelial neoplasia.

Authors:  S K Jonas; C Benedetto; A Flatman; R H Hammond; L Micheletti; C Riley; P A Riley; D J Spargo; M Zonca; T F Slater
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

6.  The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.

Authors:  Jinyun Li; Chongchang Zhou; Haojie Zhou; Tianlian Bao; Tengjiao Gao; Xiangling Jiang; Meng Ye
Journal:  Ther Clin Risk Manag       Date:  2016-08-18       Impact factor: 2.423

7.  XH1--a new cervical carcinoma cell line and xenograft model of tumour invasion, 'metastasis' and regression.

Authors:  X Han; R Lyle; D L Eustace; R J Jewers; J M Parrington; A Das; T Chana; B Dagg; S Money; T D Bates
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.